Company news
Precipio, Inc. news in 2024
Precipio, Inc.'s news releases, calls and decks from 2024, newest first.
Precipio Announces Q3 2024 Shareholder Update Call Conference Call to be held on Form 8 K
November 7, 2024
Precipio Announces Q3-2024 Shareholder Update Call
November 5, 2024
Precipio Expands Bloodhound™ MPN Panel by Adding CALR Mutation Subtyping
October 7, 2024
Precipio Announces Employee Stock Option Plan Repricing
September 5, 2024
Precipio Announces Q2-2024 Shareholder Update Call
August 14, 2024
Precipio Reports $0.3M cash generated by operations (unaudited) in Q2-2024, as the company advances towards breakeven
July 24, 2024
Precipio Reports $4.4M for Q2-2024 (unaudited) Revenues, a leap of 30% from Q1-2024
July 16, 2024
Precipio Inc. Announces Adjournment of Annual Meeting of Stockholders
June 12, 2024
Precipio Provides Status Update on Current Business Matters
June 11, 2024
Precipio Secures a short-term $500K Credit Facility
May 5, 2024
Precipio Announces Year end 2023 Shareholder Update Call
March 24, 2024
Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY
February 12, 2024
Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for Cancer
February 5, 2024
Precipio’s Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter
January 22, 2024
Precipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in Japan
January 16, 2024
Precipio Announces Christina Valauri joins the Board of Directors
January 1, 2024